Glass House Brands (GLAS) Cash & Current Investments (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Cash & Current Investments of $27.9 million for Q1 2026, down 25.76% year-over-year from $37.6 million in Q1 2025, and up 40.69% quarter-over-quarter from $19.8 million in Q4 2025.
Glass House Brands (GLAS) Cash & Current Investments (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Cash & Current Investments for 7 consecutive years, with $27.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments fell 25.76% year-over-year to $27.9 million; the TTM figure through Mar 2026 stood at $27.9 million (down 25.76% YoY), while the FY2025 annual figure was $19.8 million, down 46.24% from the prior year.
- Cash & Current Investments grew to $27.9 million in Q1 2026 per GLAS's latest filing, from $19.8 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $44.2 million in Q2 2025 and bottomed at $14.1 million in Q4 2022.
- Historically, Cash & Current Investments has averaged $28.9 million across 5 years, with a median of $27.9 million in 2026.
- Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 92.54% — and 2023, when it jumped 129.96%.
- Glass House Brands' Cash & Current Investments stood at $14.1 million in 2022, then surged by 129.96% to $32.5 million in 2023, then gained by 13.53% to $36.9 million in 2024, then plunged by 46.24% to $19.8 million in 2025, then jumped by 40.69% to $27.9 million in 2026.
- Business Quant data shows GLAS's Cash & Current Investments at $27.9 million in Q1 2026, $19.8 million in Q4 2025, and $29.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Glass House Brands | 829.33 Mn | 810.78 Mn | 15.77 Mn | 18.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.93 Mn |
| Dec 31, 2025 | 19.85 Mn |
| Sep 30, 2025 | 29.77 Mn |
| Jun 30, 2025 | 44.20 Mn |
| Mar 31, 2025 | 37.62 Mn |
| Dec 31, 2024 | 36.92 Mn |
| Sep 30, 2024 | 38.06 Mn |
| Jun 30, 2024 | 28.88 Mn |
| Mar 31, 2024 | 27.41 Mn |
| Dec 31, 2023 | 32.52 Mn |
| Sep 30, 2023 | 40.89 Mn |
| Jun 30, 2023 | 25.69 Mn |
| Mar 31, 2023 | 19.37 Mn |
| Dec 31, 2022 | 14.14 Mn |
| Sep 30, 2022 | 20.54 Mn |
| Jun 30, 2022 | 20.45 Mn |
| Mar 31, 2022 | 27.83 Mn |
| Dec 31, 2021 | 54.07 Mn |
| Sep 30, 2021 | 28.86 Mn |
| Jun 30, 2021 | 134.28 Mn |